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Objective. To assess the efficacy of tocilizumab (TCZ) for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis.
Methods. We conducted a multicenter study of patients with JIA-associated uveitis that was refractory to conventional immunosuppressive drugs and antitumor necrosis factor (anti-TNF) agents.
Results. We assessed 25 patients (21 female; 47 affected eyes) with a mean 6 SD age of 18.5 6 8.3 years. Uveitis was bilateral in 22 patients. Cystoid macular edema was present in 9 patients. Ocular sequelae found at initiation of TCZ included cataracts (n 5 13), glaucoma (n 5 7), synechiae (n 5 10), band keratopathy (n 5 12), maculopathy (n 5 9), and amblyopia (n 5 5). Before TCZ, patients had received corticosteroids, conventional immunosuppressive drugs, and biologic agents (median 2 [range 1-5]), including adalimumab (n 5 24), etanercept (n 5 8), infliximab (n 5 7), abatacept (n 5 6), rituximab (n 5 2), anakinra (n 5 1), and golimumab (n 5 1). Patients received 8 mg/kg TCZ intravenously every 4 weeks in most cases. TCZ yielded rapid and maintained improvement in all ocular parameters. After 6 months of therapy, 79.2% of patients showed improvement in anterior chamber cell numbers, and 88.2% showed improvement after 1 year. Central macular thickness measured by optical coherence tomography in patients with cystoid macular edema decreased from a mean 6 SD of 401.7 6 86.8 mm to 259.1 6 39.5 mm after 6 months of TCZ (P 5 0.012). The best-corrected visual acuity increased from 0.56 6 0.35 to 0.64 6 0.32 (P < 0.01). After a median follow-up of 12 months, visual improvement persisted, and complete remission of uveitis was observed in 19 of 25 patients. Significant reduction in the prednisone dosage was also achieved. The main adverse effects were severe autoimmune thrombocytopenia in 1 patient, pneumonia and then autoimmune anemia and thrombocytopenia in 1 patient, and viral conjunctivitis and bullous impetigo in 1 patient.
Conclusion. TCZ appears to be a useful therapy for severe refractory JIA-associated uveitis.
Uveitis is the most common and challenging extraarticular manifestation of juvenile idiopathic arthritis (JIA) and affects ;10-15% of patients (1-2). Risk factors include antinuclear antibody (ANA) positivity, young age at disease onset, female sex, and oligoarticular arthritis (2) (3) (4) (5) (6) (7) (8) . Up to 38% of patients with JIAassociated uveitis develop severe visual impairment, and up to 16-22% become blind (9,10), with cystoid macular edema being the most common cause of visual loss (11) .
JIA-associated uveitis typically presents as a chronic bilateral nongranulomatous anterior uveal inflammation with an insidious and silent course that may lead to structural ocular tissue damage and subsequent visual loss (12) . Long-term ocular complications include cataracts, band keratopathy, posterior synechiae, glaucoma, hypotony, and maculopathy (13, 14) .
Adequate management is crucial to avoid visual impairment. Topical and systemic corticosteroids constitute first-line therapy, often combined with conventional immunosuppressive drugs, mainly methotrexate (MTX) (15) (16) (17) . Anti-tumor necrosis factor (anti-TNF) agents have substantially improved the prognosis of patients with JIA with or without uveitis. According to a recent expert panel report on the use of anti-TNF agents in patients with JIA-related uveitis (18) , infliximab (IFX) or adalimumab (ADA) should be considered as the secondline immunomodulatory treatment after MTX. Although treatment with anti-TNF agents usually leads to clinical improvement, in some patients, these agents cannot control intraocular inflammation. In other patients, anti-TNF agents may be contraindicated, or they may have to be withdrawn due to adverse effects. These cases represent a major clinical challenge.
Tocilizumab (TCZ) is a humanized monoclonal antibody that binds to the cellular receptor for interleukin-6 (IL-6), inhibiting the proinflammatory effects of this cytokine. This biologic agent has been approved for the treatment of polyarticular and systemic JIA in patients 2 years of age and older. However, information on the efficacy of TCZ for the treatment of severe JIA-associated uveitis is scarce and in most cases it is based on studies that included a small number of patients (19) (20) (21) (22) . Taking all of these considerations into account, in the present study we aimed to assess the efficacy of TCZ in patients with JIAassociated uveitis refractory to conventional immunosuppressive drugs and at least 1 anti-TNF agent.
PATIENTS AND METHODS
Study design and enrollment criteria. We set up a multicenter retrospective study that included patients with JIA-associated uveitis. Chart review of all eligible patients was performed. Patients were followed up in the Uveitis Units of 8 referral centers in Spain.
JIA was diagnosed according to the International League of Associations for Rheumatology revised 2001 classification criteria (6) . The diagnosis was always confirmed by a pediatric rheumatologist. To be included in the study, JIA patients had to have refractory uveitis with partial or no response to corticosteroids, conventional synthetic immunosuppressive drugs, and biologic therapy, including at least 1 anti-TNF agent.
This is an observational study of TCZ therapy in patients with refractory uveitis due to JIA. According to Spanish National Regulation, in cases such as this in which patients are treated with a drug for an off-label use, such as TCZ in uveitis, Institutional Review Board approval is not mandatory. However, written informed consent is mandatory, and it was requested and obtained from all patients.
The conventional immunosuppressive drugs and biologic agents and dosages used before TCZ were as follows: MTX (10-15 mg/m 2 /week), hydroxychloroquine (3-5 mg/kg/day), cyclosporin A (,5 mg/kg/day), leflunomide (10 mg/day for children weighing 20-40 kg and 20 mg/day for children weighing .40 kg), ADA (24 mg/m 2 of body surface area subcutaneously every 2 weeks), etanercept (ETN; 0.8 mg/kg up to 50 mg per dose administered subcutaneously once a week), IFX (5 mg/kg administered intravenously [IV] at 0, 2, and 4 weeks followed by a maintenance dose every 4 weeks), abatacept (ABA; 10 mg/kg IV at 0, 2, and 6 weeks followed by a maintenance dose every 8 weeks), rituximab (RTX; a single course of 2 IV doses of 1 gm each administered 2 weeks apart), and anakinra (1 mg/kg/day administered subcutaneously).
Patients with malignancy or systemic infectious diseases, including hepatitis B or hepatitis C virus infection, were excluded before the initiation of TCZ treatment, as previously described (23) (24) (25) (26) (27) (28) . As indicated in the Spanish National Guidelines, to exclude latent tuberculosis, tuberculin skin testing (purified protein derivative) and/or an interferon-g assay (QuantiFeron) and chest radiography were performed in all patients receiving biologic agents. If latent tuberculosis was present, prophylactic treatment with isoniazid was initiated at least 4 weeks before initiation of treatment with the biologic agent and maintained for 9 months. Uveitis was anatomically classified according to the International Uveitis Study Group classification criteria (29) . Remission was defined as the presence of inactive disease for at least 3 months. Since uveitis is an off-label indication for TCZ, written informed consent was requested and obtained from all of the patients or their parents.
Outcome variables. Intraocular inflammation, macular thickness, visual acuity, and corticosteroid-sparing effect were the outcome variables. They were assessed in each center according to a predefined follow-up protocol and recorded at baseline, at 1 week and at 1, 3, 6, and 12 months. The degree of intraocular inflammation was evaluated according to the method of the Standardization of Uveitis Nomenclature (SUN) Working Group (30) . The Nussenblat scale was used to evaluate the degree of vitritis (31) .
Inactive anterior uveitis was defined as ,1 cell per field in the anterior chamber on slit lamp examination (grade 0). Following the SUN Working Group recommendations, improved uveitis activity was defined as either a 2-step decrease in the level of inflammation or a decrease to grade 0, and worsening activity was defined as either a 2-step increase in the level of inflammation or an increase to grade 4 (30) . A similar definition was used for the improvement of vitreous haze (30) . Data were reported for each affected patient.
Retinal vasculitis was defined as retinal angiographic leakage, staining, and/or occlusion on fluorescein angiography (32) . Choroiditis and retinitis were considered active or inactive depending on the presence or absence of activity data on the ophthalmic examination and/or in the fluorescein angiogram.
Macular thickness was measured by high-definition optical coherence tomography (OCT). All high-definition OCT scans were performed using Cirrus high-definition OCT (Carl Zeiss). Scans were obtained using a 512 3 128 scan pattern. Macular thickening was defined as a macular thickness of .250 mm, and cystoid macular edema was considered to be present when macular thickness was .300 mm.
The best-corrected visual acuity was determined using the Snellen chart. According to this test, 20/20 vision (or 20/20 visual acuity) is considered normal vision, meaning that the subject is able to read at 20 feet a letter that most individuals should be able to read at 20 feet. For the purpose of the present study, 20/20 vision (normal vision) is expressed as 1.0, and 0/20 vision is expressed as 0.0. A relapse was considered to be present if an asymptomatic patient experienced a new flare of uveitis (31) .
Statistical analysis. Results are expressed as the mean 6 SD or median (interquartile range [IQR]) as appropriate. For discontinuous data, the percentage of improvement from baseline was calculated and compared by chi-square test or Fisher's exact test as appropriate. Wilcoxon's signed rank test was used to compare continuous variables before and after TCZ therapy. In the case of anterior chamber cells and vitreous haze (ordinal variables), each patient was considered as an independent variable. To compare best-corrected visual acuity and OCT differences, the results were reported considering the number of affected eyes. Statistical analysis was performed using Statistica software (StatSoft).
RESULTS
Baseline characteristics of the patients. Twentyfive patients (47 affected eyes) with JIA-associated uveitis refractory to conventional immunosuppressive therapy and at least 1 biologic agent, including anti-TNF drugs, were studied. The main epidemiologic features are summarized in Table 1 . There were more female patients (n 5 21) than male patients (n 5 4). At the initiation of TCZ treatment, the mean 6 SD age was 18.5 6 8.3 years (range 8-38 years). Oligoarticular JIA was the disease subtype most frequently associated with uveitis. In most cases uveitis was bilateral, and the most frequent pattern was anterior uveitis. The median time from JIA-associated uveitis diagnosis to the initiation of TCZ therapy was 106 months (IQR 24-198 months). Ocular sequelae found at initiation of TCZ therapy included cataracts (n 5 13), glaucoma (n 5 7), synechiae (n 5 10), band keratopathy (n 5 12), maculopathy (n 5 9), and amblyopia (n 5 5).
Therapeutic regimens before initiation of TCZ treatment. Intraocular corticosteroids were prescribed to 11 patients. One patient was also treated with IV pulse methylprednisolone. Patients had also received conventional immunosuppressive drugs prior to TCZ, mainly MTX (n 5 24), and a median of 2 biologic agents (IQR 1-2; range 1-5). These agents were ADA (n 5 24), ETN (n 5 8), IFX (n 5 7), ABA (n 5 6), RTX (n 5 2), anakinra (n 5 1), and golimumab (n 5 1).
The biologic agents used in these 25 patients with severe refractory JIA-associated uveitis that required TCZ therapy are shown in Figure 1 . In all cases, the initial biologic agent was an anti-TNF drug (ADA in 16 patients, IFX in 3 patients, and ETN in 6 patients). The main reasons for starting biologic therapy in these patients were uveitis (16 cases), arthritis (6 cases), and uveitis plus arthritis (3 cases). The main reasons for starting TCZ therapy were uveitis (20 cases) and uveitis plus arthritis (5 cases). TCZ was used in combination with conventional immunosuppressive drugs in 22 of 25 patients (MTX in 14 patients, leflunomide in 5 patients, cyclosporin A in 2 patients, and pulse methylprednisolone in 1 patient). The TCZ dosage regimen was 8 mg/kg IV every 4 weeks (n 5 21), every 2 weeks (n 5 2), or every 8 weeks (n 5 1), or 2.9 mg/kg subcutaneously every week (n 5 1). In 4 patients, the interval between TCZ doses was increased because of sustained clinical remission. Clinical efficacy of TCZ. All of the outcome variables showed improvement following TCZ therapy (Figures 2 and 3) . Information on efficacy after 6 months of follow-up was available for 24 patients. In the remaining patient the follow-up period was only 3 months because the biologic agent had to be discontinued due to severe thrombocytopenia. At the end of the present study 17 patients had completed 1 year of follow-up.
After 6 months of TCZ therapy, the mean 6 SD best-corrected visual acuity increased from 0.56 6 0. As shown in Figures 3A and B , rapid and maintained improvement was achieved following TCZ therapy. Three patients had choroiditis (4 eyes), 4 patients had retinal vasculitis (6 eyes), and 3 patients had retinitis (4 eyes) at baseline. These 3 complications were present in only 1 eye after 6 months of treatment. At the beginning of TCZ treatment, 10 patients (17 eyes) had macular thickening (OCT .250 mm), and 9 patients (14 eyes) had cystoid macular edema (OCT .300 mm). Cystoid macular edema decreased in all cases. Mean 6 SD macular thickness in patients with cystoid macular edema fell from 401.7 6 86.8 mm to 259.1 6 39.5 mm at 6 months (P 5 0.012) and to 252.5 6 30.1 mm at 1 year (P 5 0.027).
Reduction in the daily median dose of prednisone (or equivalent) from 10 mg (IQR 0-20) at baseline to 2.5 mg (IQR 0-5) at 6 months and to 0 mg (IQR 0-5) at 1 year was also achieved (P 5 0.001 for both comparisons). These data represent a reduction in the prednisone dose of 69.4 6 6.4% between baseline and month 6 of TCZ therapy and 82.2 6 7.1% between baseline and 1 year of TCZ therapy. After 1 year of treatment, 6 of the 25 patients were still receiving treatment with oral prednisone, but in all of these patients a dose reduction was achieved.
Follow-up and side effects. TCZ was generally well tolerated in most patients. After a median followup of 12 months (IQR 6-24 months), ocular remission was obtained in 19 (76%) of 25 patients. As discussed above, this biologic agent had to be withdrawn in 1 patient after 3 months of therapy because of severe autoimmune thrombocytopenia. Another patient had pneumonia 1 year after the beginning of TCZ treatment. The drug was temporarily discontinued and subsequently restarted. However, after 30 months of treatment, TCZ had to be withdrawn due to autoimmune anemia and thrombocytopenia. A third patient experienced viral conjunctivitis and bullous impetigo that required temporary TCZ discontinuation. The therapy was later restarted, with no new side effects during follow-up. Finally, in 1 of the 25 patients, TCZ therapy was withdrawn because of lack of efficacy.
DISCUSSION
We studied 25 patients with severe JIAassociated uveitis refractory to conventional immunosuppressive drugs and at least 1 biologic agent including anti-TNF drugs. Interestingly, most patients experienced a favorable response to TCZ.
Ocular involvement is the most severe extraarticular manifestation in patients with JIA (1-3). Predictive factors for poor visual outcome include the severity of uveitis at the initial examination (33), the onset of visual manifestations before or at the time of JIA diagnosis, a shorter time period between the onset of arthritis and ocular involvement (34) , and male sex (35) .
JIA-associated uveitis mainly affects the anterior chamber, and the prognosis is usually favorable. However, in approximately one-third of the cases, ocular 
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CALVO-R IO ET AL inflammation is more severe and in these cases immunosuppressive agents are needed due to vision-threatening complications (35) . In this regard, despite being rare manifestations, retinitis and retinal vasculitis were seen in some of the patients in our series and in previously published studies (11, 36) . Macular edema is one of the most frequent ocular complications, affecting 3-47% of patients in previous studies (38) . It is the cause of legal blindness in 8% of children with active uveitis. The pathophysiology of inflammatory macular edema is still unclear, although the breakdown of the inner blood-retinal barrier probably represents its main mechanism (37) .
With respect to the therapeutic regimen for JIAassociated uveitis, topical corticosteroids usually represent the first-line agents (38) . Short-acting mydriatics and cycloplegics should also be added to keep the pupil mobile, and thus prevent the development of posterior synechiae. However, the frequency of administration of these drugs should be limited, because constant cycloplegia may lead to amblyopia in some children (39) , and synechiae can develop in dilated position if the pupils remain immobile (40) . In patients unresponsive to topical treatment, oral corticosteroids and conventional immunosuppressive drugs, mainly MTX, are the drugs of choice (15) (16) (17) . Mycophenolate mofetil (41, 42) and cyclosporin A, as monotherapy or combined with MTX, have shown promising results in some cases of JIA-associated uveitis (43) .
Biologic agents have become the cornerstone of therapy in patients unresponsive to or intolerant of (18) . The problem arises when uveitis is also refractory to these biologic agents. In these cases, we need to act on other therapeutic targets. ABA, a fusion protein that inhibits the costimulation and activation of T lymphocytes, has been approved for the treatment of polyarticular JIA in children older than 6 years. However, several studies have yielded inconsistent results on the potential efficacy of ABA in JIA-associated uveitis refractory to conventional immunosuppressive drugs and other biologic agents (45) (46) (47) .
RTX has been another biologic agent evaluated in these cases. It is a monoclonal antibody that targets CD20, a specific B cell surface antigen. This drug is not commonly used to treat patients with JIA, and it has not been approved for this indication. However, efficacy of RTX in JIA-associated uveitis has been shown in retrospective studies (48) (49) (50) .
TCZ is a humanized recombinant antibody that binds to the IL-6 receptor and inhibits the downstream signaling of IL-6 and its proinflammatory effects. It has recently been approved for the management of polyarticular and systemic JIA in patients older than 2 years. However, only single case reports and a small case series assessing the efficacy of TCZ for the management of uveitis and cystoid macular edema in patients with JIA have been published (19) (20) (21) (22) 51) (Table 2 ). The subjects previously described by Ad an et al (20, 21) were excluded from the present study. The promising results of the studies described in Table 2 led us to conduct the present analysis of our data. According to our results, TCZ may be an effective therapy for severe JIA-associated uveitis refractory to conventional immunosuppressive and biologic drugs including anti-TNF and other biologic agents such as RTX or ABA. In this regard, in our study, we observed an improvement in all of the ocular parameters analyzed. Regarding safety data, the drug was generally well tolerated in most patients with an adverse event profile similar to that previously published (19) (20) (21) (22) .
To our knowledge, our study includes the largest series of patients diagnosed as having JIA-associated uveitis refractory to conventional immunosuppressive drugs and other biologic agents who were treated with TCZ. Nevertheless, it has the limitations derived from its observational nature. In conclusion, the present study supports the claim that TCZ may be a useful biologic agent in severe JIA-associated refractory uveitis.
